title: Alternate coupling of receptors to Gs and Gi in pancreatic and submandibular gland cells.
abstract: Many Gs-coupled receptors can activate both cAMP and Ca2+ signaling pathways. Three mechanisms for dual activation have been proposed. One is receptor coupling to both Gs and G15 (a Gq class heterotrimeric G protein) to initiate independent signaling cascades that elevate intracellular levels of cAMP and Ca+2, respectively. The other two mechanisms involve cAMP-dependent protein kinase-mediated activation of phospholipase Cbeta either directly or by switching receptor coupling from Gs to Gi. These mechanisms were primarily inferred from studies with transfected cell lines. In native cells we found that two Gs-coupled receptors (the vasoactive intestinal peptide and beta-adrenergic receptors) in pancreatic acinar and submandibular gland duct cells, respectively, evoke a Ca2+ signal by a mechanism involving both Gs and Gi. This inference was based on the inhibitory action of antibodies specific for Galphas, Galphai, and phosphatidylinositol 4,5-bisphosphate, pertussis toxin, RGS4, a fragment of beta-adrenergic receptor kinase and inhibitors of cAMP-dependent protein kinase. By contrast, Ca2+ signaling evoked by Gs-coupled receptor agonists was not blocked by Gq class-specific antibodies and was unaffected in Galpha15 -/- knockout mice. We conclude that sequential activation of Gs and Gi, mediated by cAMP-dependent protein kinase, may represent a general mechanism in native cells for dual stimulation of signaling pathways by Gs-coupled receptors.
authors.affiliation: Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
authors.forename: X
authors.initials: X
authors.lastname: Luo
authors.forename: W
authors.initials: W
authors.lastname: Zeng
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: S
authors.initials: S
authors.lastname: Popov
authors.forename: I
authors.initials: I
authors.lastname: Davignon
authors.forename: T M
authors.initials: TM
authors.lastname: Wilkie
authors.forename: S M
authors.initials: SM
authors.lastname: Mumby
authors.forename: S
authors.initials: S
authors.lastname: Muallem
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000276:immunology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism*; D007545:Isoproterenol / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D010179:Pancreas / Q000378:metabolism*; D037342:Pertussis Toxin; D019269:Phosphatidylinositol 4,5-Diphosphate / Q000276:immunology; D011506:Proteins / Q000494:pharmacology; D020710:RGS Proteins; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism*; D018005:Receptors, Vasoactive Intestinal Peptide / Q000378:metabolism; D015398:Signal Transduction; D013363:Submandibular Gland / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology; D051552:beta-Adrenergic Receptor Kinases
chemical_list: D000906:Antibodies; D004791:Enzyme Inhibitors; D019269:Phosphatidylinositol 4,5-Diphosphate; D011506:Proteins; D020710:RGS Proteins; D011943:Receptors, Adrenergic, beta; D011956:Receptors, Cell Surface; D018005:Receptors, Vasoactive Intestinal Peptide; D010566:Virulence Factors, Bordetella; C098799:RGS4 protein; D014660:Vasoactive Intestinal Peptide; D000242:Cyclic AMP; D037342:Pertussis Toxin; D017868:Cyclic AMP-Dependent Protein Kinases; D051552:beta-Adrenergic Receptor Kinases; D019204:GTP-Binding Proteins; D007545:Isoproterenol; D002118:Calcium